Introduction For cisplatin-ineligible patients, approval of first-line immune-checkpoint inhibitor therapy relies on the programmed death ligand 1 (PD-L1) expression assay employed, namely, the combined positive score (CPS) or immune cell (IC) score. This study compares PD-L1 diagnostic scores and...
For instance, the tumor proportion score (TPS) considers the proportion of tumor cells with PD-L1 expression, whilst the combined positive score (CPS) examines both the tumor cells and immune cells, with variable use across cancer types and clinical trials13,14,15,16. Recent studies have ...
PD-L1 combined positive scores (CPS) were 20, 50, 5 and 30, respectively. The Ki-67 proliferative index were 20%, 20%, 10% and 30%, respectively. In low-grade cases, the mean values of CD4 and CD8 positive T-lymphocytes were 123.0/mm 2 and 100.5/mm 2, respectively. The PD-L1 ...
The combined positive score (CPS) and tumor proportion score (TPS) have been developed to evaluate programmed death ligand-1 (PD-L1) expression, especially due to the potential benefit of the targeted therapy. However, the prognostic value of PD-L1 scoring systems in gastric cancer (GC) ...
PD-L1 expression was retrospectively assessed using the VENTANA PD-L1 SP263 IHC assay, which is approved by the US Food and Drug Administration for the assessment of PD-L1 expression [21]. The PD-L1 combined positive score (CPS) was calculated using the formula: CPS = [(number of PD−...
[17]. Additionally, the response rate for trastuzumab plus pembrolizumab in trastuzumab-resistant, PD-L1-positive metastatic HER2-positive breast cancer was only 15% [18]. Atezolizumab, when combined with trastuzumab-emtansine (T-DM1), did not improve PFS and was associated with an increase in ...
In the open-label, randomized, phase III KEYNOTE-181 trial (NCT02564263), pembrolizumab was associated with a statistically significant improvement in OS compared with either paclitaxel, docetaxel, or irinotecan in patients with a PD-L1 combined positive score (CPS) ≥10, regardless of histology....
Nakayama: Yeah, and it's not as easy as you would think. It's not [a situation where you just check if they] have PD-1 or PD-L1 or whatnot when [you] look at [the] tumor. They actually will sometimes make these combined positive scores [CPS], and there are other scoring system...
PD-L1表达使用IHC检测(TPS/CPS),TMB 10~16 mut/Mb组中,PD-L1表达<1的比例更高,且没有PD-L1表达≥50的患者;而TMB≥16 mut/Mb组中,PD-L1(TPS,tumor proportion scores)表达<1,1~50,≥50三个亚组的ORR分别是33.3%(5/15),40.0%(2/5),50.0%(3/6);PD-L1(CPS,combined positive scores)表达<1,...
Efforts are being made to identify biomarkers that predict the response to ICI treatment, such as combined positive score (CPS) of PD-L1 expression, tumor mutational burden or microsatellite instability [[8],[9],[10]], but this invasive way to obtain tissues might cause treatment delay and ...